AmplifAI Health, a KAUST-backed health-tech startup, has received Saudi Food and Drug Authority (SFDA) approval for its AI-driven diabetic foot screening software — the first of its kind worldwide. This milestone marks a significant step in advancing AI-driven healthcare solutions for the Kingdom.
With a goal of reaching 10 million diabetic and prediabetic patients in the Kingdom by 2026, AmplifAI’s high-tech solution could transform healthcare accessibility and early intervention for diabetic foot ulcers, advancing both patient outcomes and diagnostic capabilities in Saudi Arabia. Its breakthrough technology leverages thermal imaging and AI.
Supported by KAUST and partners such as Wa’ed Ventures and Plug and Play Tech Center, AmplifAI exemplifies the University’s key role in advancing medical innovation and digital transformation. AmplifAI’s progress underscores KAUST’s commitment to supporting in-Kingdom deep-tech entrepreneurship to drive meaningful healthcare solutions.
Early last year, KAUST signed a memorandum of understanding with AmplifAI to develop new disease detection systems combining artificial intelligence and HyplexTM — a hyperspectral-imaging technology by KAUST Professor of Electrical Engineering Andrea Fratalocchi, capable of collecting terabytes of data in one second.